

## **Dong Wook Kim, Ph.D.**

Position: research professor

Department: Department of Biochemistry

Affiliation: College of Veterinary Medicine Seoul National University

Office: 02-880-1288 (010-6225-5502)

E-mail: bellocan@snu.ac.kr

---

### **Education**

Mar. 2003 – Feb. 2006	Ph.D	Department of Molecular Medicine, Chungnam National University
Mar. 2001 – Feb. 2003	M.S.	Department of Molecular Medicine, Chungnam National University
Mar. 1993 – Feb. 2001	B.S.	Department of Genetic Engineering, Kyungpook National University

### **Professional Experience**

Dec. 2016 – Current	Research Professor	Department of Biochemistry, College of Veterinary Medicine Seoul National University
Jan. 2014 – Nov. 2016	Research Professor.	Leading-edge Research Center for Drug Discovery and Development for Diabetes and Metabolic disease Kyungpook National University Medical Center
Jan. 2009 – Nov. 2013	Visiting fellow.	Gene Regulation Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health
Mar. 2006 – March. 2008	Postdoc.	Department of Molecular Medicine, Chungnam National University

### **Academic Society**

yyyy.mm-yyyy.mm	Position	society
-----------------	----------	---------

### **Publications**

Choi YJ, Jeong S, Yoon KA, Sung HJ, Cho HS, Kim DW, Cho JY. Deficiency of DGCR8 increases bone formation through downregulation of miR-22 expression. *Bone*. 2017 Oct;103:287-294. doi: 10.1016/j.bone.2017.07.021. Epub 2017 Jul 21.

Kim DW, Park JW, Willingham MC, Cheng SY. A histone deacetylase inhibitor improves hypothyroidism caused by a TR $\alpha$ 1 mutant. *Hum Mol Gene*. 2014 May 15;23(10):2651-64. doi: 10.1093/hmg/ddt660. Epub 2013 Dec 30.

Kim DW, Walker RL, Meltzer PS, Cheng SY. Complex temporal changes in TGF $\beta$  oncogenic signaling drive thyroid carcinogenesis in a mouse model. *Carcinogenesis*. 2013 Oct;34(10):2389-2400. Epub 2013 May 22

Fozzatti L, Kim DW, Park JW, Willingham MC, Hollenberg AN, Cheng SY. Nuclear receptor corepressor

(NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor  $\alpha$ . Proc Natl Acad Sci U S A. 2013 May 7;110(19):7850-5.

Kim DW, Zhao L, Hanover J, Willingham M, Cheng SY. Thyroid hormone receptor  $\beta$  suppresses SV40-mediated tumorigenesis via novel nongenomic actions. Am J Cancer Res. 2012;2(5):606-19. Epub 2012 Aug 23.

O Shea PJ, Kim DW, Logan JG, Davis S, Walker RL, Meltzer PS, Cheng SY, Williams GR. Advanced bone formation in mice with a dominant-negative mutation in the thyroid hormone receptor  $\beta$  gene due to activation of Wnt/ $\beta$ -catenin signaling. J Biol Chem. 2012 May 18;287(21):17812-22. doi: 10.1074/jbc.M111.311464. Epub 2012 Mar 22.

Guigon CJ, Kim DW, Willingham MC, Cheng SY. Mutation of thyroid hormone receptor- $\beta$  in mice predisposes to the development of mammary tumors. Oncogene. 2011 Jul 28;30(30):3381-90. doi: 10.1038/onc.2011.50

Lee SJ\*, Lee MH\*, Kim DW\*, Lee S, Huang S, Ryu MJ, Kim YK, Kim SJ, Kim SJ, Hwang JH, Oh S, Cho H, Kim JM, Lim DS, Jo YS, Shong M. Cross-Regulation between Oncogenic BRAF Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma. PLoS One. 2011 Jan 13;6(1):e16180. \*Contributed equally

Hwang JH\*, Kim DW\*, Jo EJ, Kim YK, Jo YS, Park JH, Yoo SK, Park MK, Kwak TH, Kho YL, Han J, Choi HS, Lee SH, Kim JM, Lee I, Kyung T, Jang C, Chung J, Kweon GR, Shong M. Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes. 2009 Apr;58(4):965-74. \*Contributed equally

Kim DW, Chung HK, Park KC, Hwang JH, Jo YS, Chung J, Kalvakolanu DV, Resta N, Shong M. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol Endocrinol. 2007 Dec;21(12):3039-49.

Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Kweon GR, Jo KW, Shong M. An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/PTC kinases. J Clin Endocrinol Metab. 2006 Oct;91(10):4070-6.

Jung HS, Kim DW, Jo YS, Chung HK, Song JH, Park JS, Park KC, Park SH, Hwang JH, Jo KW, Shong M. 2005. Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol. 2005. Nov;19(11):2748-59.

Hwang ES\*, Kim DW\*, Hwang JH, Jung HS, Suh JM, Park YJ, Chung HK, Song JH, Park KC, Park SH, Yun HJ, Kim JM, Shong M. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1 dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases. Mol Endocrinol. 2004 Nov;18(11):2672-84. \*Contributed equally

Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol. 2003 Jul;17(7):1382-94